Skip to content
2000
image of Amelioration of Anxiety Disorders Using Nanotechnology-Based Drug Delivery Systems

Abstract

Introduction/Objective

Anxiety is a natural response to a potential threat that helps individuals prepare for it. However, when it becomes chronic, excessive, and uncontrollable, it is classified as pathological. Anxiety disorders are among the most frequently encountered psychiatric conditions and have shown a rising trend in prevalence. Current therapeutic approaches are limited due to poor efficacy, reduced bioavailability, side effects, and the challenge of misdiagnosis. This review aims to explore nanotechnology-based drug delivery systems as a novel strategy to overcome these limitations.

Methods

The recent scientific literature was reviewed, focusing on nanotechnology-enabled drug delivery systems in the treatment of anxiety disorders. Emphasis was placed on formulations that improve therapeutic efficacy and safety, including niosomes, liposomes, polymeric nanocapsules, chitosan nanoparticles, solid lipid nanoparticles, and nanostructured lipid carriers.

Results

Nanotechnology has emerged as a promising tool for targeted drug delivery at the nanometric scale. These systems offer controlled release, improved bioavailability, site-specific targeting, enhanced stability, and reduced adverse effects. Various nanoformulations have demonstrated potential efficacy in managing anxiety disorders more effectively than conventional approaches.

Discussion

The application of nanotechnology addresses serious limitations of current therapies, particularly poor brain targeting and systemic side effects. The novel drug delivery systems can provide safe, effective, and patient-compliant options for anxiety management.

Conclusion

This review highlights the promise of nanotechnology-driven formulations in the treatment of anxiety disorders and discusses their current status and future prospects in therapeutic applications.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cprr/10.2174/0126660822381093251114064131
2026-02-20
2026-03-03

  • From This Site

    /content/journals/cprr/10.2174/0126660822381093251114064131
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kieling C. Buchweitz C. Caye A. Worldwide prevalence and disability from mental disorders across childhood and adolescence: Evidence from the global burden of disease study. JAMA Psychiatry 2024 81 4 347 356 10.1001/jamapsychiatry.2023.5051 38294785
    [Google Scholar]
  2. Mangolini V.I. Andrade L.H. Lotufo-Neto F. Wang Y.P. Treatment of anxiety disorders in clinical practice: A critical overview of recent systematic evidence. Clinics (São Paulo) 2019 74 1316 10.6061/clinics/2019/e1316 31721908
    [Google Scholar]
  3. Cao H. Wu Y. Yin H. Sun Y. Yuan H. Tao M. Global trends in the incidence of anxiety disorders from 1990 to 2019: Joinpoint and Age-Period-Cohort Analysis Study. JMIR Public Health Surveill. 2024 10 1 49609 10.2196/49609 38285497
    [Google Scholar]
  4. LeDoux J.E. Pine D.S. Using neuroscience to help understand fear and anxiety: A two-system framework. Am. J. Psychiatry 2016 173 11 1083 1093 10.1176/appi.ajp.2016.16030353 27609244
    [Google Scholar]
  5. American Psychiatric Association American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC American Psychiatric Association 2013
    [Google Scholar]
  6. Huang C.W. Wee P.H. Low L.L. Prevalence and risk factors for elevated anxiety symptoms and anxiety disorders in chronic kidney disease: A systematic review and meta-analysis. Gen. Hosp. Psychiatry 2021 69 27 40 10.1016/j.genhosppsych.2020.12.003 33516963
    [Google Scholar]
  7. Vroling M.S. de Jong P.J. Threat-confirming belief bias and symptoms of anxiety disorders. J. Behav. Ther. Exp. Psychiatry 2010 41 2 110 116 10.1016/j.jbtep.2009.11.002 19942212
    [Google Scholar]
  8. Allgulander C. Anxiety as a risk factor in cardiovascular disease. Curr. Opin. Psychiatry 2016 29 1 13 17 10.1097/YCO.0000000000000217 26575295
    [Google Scholar]
  9. Momin A. Rodrigues K. Stead T. Mangal R. Ganti L. The prevalence of undiagnosed anxiety: A national survey. J Affect Disord Rep 2023 13 100584 10.1016/j.jadr.2023.100584
    [Google Scholar]
  10. Craske M.G. Stein M.B. Eley T.C. Anxiety disorders. Nat. Rev. Dis. Primers 2017 3 1 17024 10.1038/nrdp.2017.24 28470168
    [Google Scholar]
  11. Blanco C. Rubio J. Wall M. Wang S. Jiu C.J. Kendler K.S. Risk factors for anxiety disorders: Common and specific effects in a national sample. Depress. Anxiety 2014 31 9 756 764 10.1002/da.22247 24577934
    [Google Scholar]
  12. Ressler K.J. Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety 2000 12 S1 2 19 10.1002/1520‑6394(2000)12:1+%3C2:AID‑DA2%3E3.0.CO;2‑4 11098410
    [Google Scholar]
  13. Bandelow B. Michaelis S. Wedekind D. Treatment of anxiety disorders. Dialogues Clin. Neurosci. 2017 19 2 93 107 10.31887/DCNS.2017.19.2/bbandelow 28867934
    [Google Scholar]
  14. Bandelow B. Current and novel psychopharmacological drugs for anxiety disorders. In: Adv. Exp. Med. Biol. 2020 1191 347 365 10.1007/978‑981‑32‑9705‑0_19
    [Google Scholar]
  15. Nguyen T.T. Dung Nguyen T.T. Vo T.K. Nanotechnology-based drug delivery for central nervous system disorders. Biomed. Pharmacother. 2021 143 112117 10.1016/j.biopha.2021.112117 34479020
    [Google Scholar]
  16. Sahu T. Ratre Y.K. Chauhan S. Bhaskar L.V.K.S. Nair M.P. Verma H.K. Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. J. Drug Deliv. Sci. Technol. 2021 63 102487 10.1016/j.jddst.2021.102487
    [Google Scholar]
  17. Patra J.K. Das G. Fraceto L.F. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnology 2018 16 1 71 10.1186/s12951‑018‑0392‑8 30231877
    [Google Scholar]
  18. Schiele M.A. Domschke K. Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders. Genes Brain Behav. 2018 17 3 12423 10.1111/gbb.12423 28873274
    [Google Scholar]
  19. Shimada-Sugimoto M. Otowa T. Hettema J.M. Genetics of anxiety disorders: Genetic epidemiological and molecular studies in humans. Psychiatry Clin. Neurosci. 2015 69 7 388 401 10.1111/pcn.12291 25762210
    [Google Scholar]
  20. Scholten W. ten Have M. van Geel C. van Balkom A. de Graaf R. Batelaan N. Recurrence of anxiety disorders and its predictors in the general population. Psychol. Med. 2023 53 4 1334 1342 10.1017/S0033291721002877 34294172
    [Google Scholar]
  21. Williams L.M. Defining biotypes for depression and anxiety based on large-scale circuit dysfunction: A theoretical review of the evidence and future directions for clinical translation. Depress. Anxiety 2017 34 1 9 24 10.1002/da.22556 27653321
    [Google Scholar]
  22. Giacobbe P. Flint A. Diagnosis and management of anxiety disorders. Continuum 2018 24 3 893 919 10.1212/CON.0000000000000607 29851884
    [Google Scholar]
  23. Martin E.I. Ressler K.J. Binder E. Nemeroff C.B. The neurobiology of anxiety disorders: Brain imaging, genetics, and psychoneuroendocrinology. Psychiatr. Clin. North Am. 2009 32 3 549 575 10.1016/j.psc.2009.05.004 19716990
    [Google Scholar]
  24. Bortoluzzi A. Salum G.A. da Rosa E.D. Chagas V.S. Castro M.A.A. Manfro G.G. DNA methylation in adolescents with anxiety disorder: A longitudinal study. Sci. Rep. 2018 8 1 13800 10.1038/s41598‑018‑32090‑1 30218003
    [Google Scholar]
  25. Ell M.A. Schiele M.A. Iovino N. Domschke K. Epigenetics of fear, anxiety and stress–focus on histone modifications. Curr. Neuropharmacol. 2024 22 5 843 865 10.2174/1570159X21666230322154158 36946487
    [Google Scholar]
  26. Domschke K. Tidow N. Schrempf M. Epigenetic signature of panic disorder: A role of glutamate decarboxylase 1 (GAD1) DNA hypomethylation? Prog. Neuropsychopharmacol. Biol. Psychiatry 2013 46 189 196 10.1016/j.pnpbp.2013.07.014 23906988
    [Google Scholar]
  27. Efstathopoulos P. Andersson F. Melas P.A. NR3C1 hypermethylation in depressed and bullied adolescents. Transl. Psychiatry 2018 8 1 121 10.1038/s41398‑018‑0169‑8 29921868
    [Google Scholar]
  28. Espallergues J. Teegarden S.L. Veerakumar A. HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience. J. Neurosci. 2012 32 13 4400 4416 10.1523/JNEUROSCI.5634‑11.2012 22457490
    [Google Scholar]
  29. Règue-Guyon M. Lanfumey L. Mongeau R. Neuroepigenetics of neurotrophin signaling: Neurobiology of anxiety and affective disorders. Prog. Mol. Biol. Transl. Sci. 2018 158 159 193 10.1016/bs.pmbts.2018.03.002 30072053
    [Google Scholar]
  30. Womersley J.S. Roeh S. Martin L. FKBP5 intron 7 methylation is associated with higher anxiety proneness and smaller right thalamus volume in adolescents. Brain Struct. Funct. 2022 227 8 2809 2820 10.1007/s00429‑022‑02577‑9 36197505
    [Google Scholar]
  31. Tafet G.E. Nemeroff C.B. Pharmacological treatment of anxiety disorders: The role of the HPA axis. Front. Psychiatry 2020 11 443 10.3389/fpsyt.2020.00443 32499732
    [Google Scholar]
  32. Morris L.S. McCall J.G. Charney D.S. Murrough J.W. The role of the locus coeruleus in the generation of pathological anxiety. Brain Neurosci. Adv. 2020 4 1 5 10.1177/2398212820930321 32954002
    [Google Scholar]
  33. Kenwood M.M. Kalin N.H. Barbas H. The prefrontal cortex, pathological anxiety, and anxiety disorders. Neuropsychopharmacology 2022 47 1 260 275 10.1038/s41386‑021‑01109‑z 34400783
    [Google Scholar]
  34. Vytal K.E. Overstreet C. Charney D.R. Robinson O.J. Grillon C. Sustained anxiety increases amygdala–dorsomedial prefrontal coupling: A mechanism for maintaining an anxious state in healthy adults. J. Psychiatry Neurosci. 2014 39 5 321 329 10.1503/jpn.130145 24886788
    [Google Scholar]
  35. Kallen V.L. Tulen J.H.M. Utens E.M.W.J. Treffers P.D.A. De Jong F.H. Ferdinand R.F. Associations between HPA axis functioning and level of anxiety in children and adolescents with an anxiety disorder. Depress. Anxiety 2008 25 2 131 141 10.1002/da.20287 17340603
    [Google Scholar]
  36. Ghasemi M. Navidhamidi M. Rezaei F. Azizikia A. Mehranfard N. Anxiety and hippocampal neuronal activity: Relationship and potential mechanisms. Cogn. Affect. Behav. Neurosci. 2022 22 3 431 449 10.3758/s13415‑021‑00973‑y 34873665
    [Google Scholar]
  37. Senkowski D. Linden M. Zubrägel D. Bär T. Gallinat J. Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder. Biol. Psychiatry 2003 53 4 304 314 10.1016/S0006‑3223(02)01478‑6 12586449
    [Google Scholar]
  38. Lydiard R.B. The role of GABA in anxiety disorders. J. Clin. Psychiatry 2003 64 Suppl. 3 21 27 12662130
    [Google Scholar]
  39. Löw K. Crestani F. Keist R. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000 290 5489 131 134 10.1126/science.290.5489.131
    [Google Scholar]
  40. Möhler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 2012 62 1 42 53 10.1016/j.neuropharm.2011.08.040 21889518
    [Google Scholar]
  41. Stein D.J. Westenberg H.G.M. Liebowitz M.R. Social anxiety disorder and generalized anxiety disorder: Serotonergic and dopaminergic neurocircuitry. J. Clin. Psychiatry 2002 63 Suppl. 6 12 19 12027115
    [Google Scholar]
  42. Cervenka S. Hedman E. Ikoma Y. Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder. Transl. Psychiatry 2012 2 5 e120 e0 10.1038/tp.2012.40 22832965
    [Google Scholar]
  43. Beyer D.K.E. Mattukat A. Freund N. Prefrontal dopamine D1 receptor manipulation influences anxiety behavior and induces neuroinflammation within the hippocampus. Int. J. Bipolar Disord. 2021 9 1 9 10.1186/s40345‑020‑00212‑2 33683478
    [Google Scholar]
  44. Sharma D. Sharma N. Pathak M. Agrawala P.K. Basu M. Ojha H. Nanotechnology-based drug delivery systems: Challenges and opportunities. In: Drug Target stimuli sensitive drug Deliv. Hoboken, New Jersey Wiley Online Library 2018 39 79 10.1016/B978‑0‑12‑813689‑8.00002‑1
    [Google Scholar]
  45. Suri S.S. Fenniri H. Singh B. Nanotechnology-based drug delivery systems. J. Occup. Med. Toxicol. 2007 2 1 16 10.1186/1745‑6673‑2‑16 18053152
    [Google Scholar]
  46. Lyseng-Williamson K.A. Duggan S.T. Keating G.M. Pegylated liposomal doxorubicin: A guide to its use in various malignancies. BioDrugs 2013 27 5 533 540 10.1007/s40259‑013‑0070‑1 24018470
    [Google Scholar]
  47. Desai N. Nanoparticle albumin-bound paclitaxel (Abraxane®). Albumin in Medicine. Otagiri M. Chuang V. Singapore Springer 2016 10.1007/978‑981‑10‑2116‑9_6
    [Google Scholar]
  48. Wilson R.J. Li Y. Yang G. Zhao C.X. Nanoemulsions for drug delivery. Particuology 2022 64 85 97 10.1016/j.partic.2021.05.009
    [Google Scholar]
  49. Borthakur P. Boruah P.K. Sharma B. Das M.R. Nanoemulsion: Preparation and its application in food industry. In: Emulsions. Amsterdam, Netherlands Elsevier 2016 153 191 10.1016/B978‑0‑12‑804306‑6.00005‑2
    [Google Scholar]
  50. Tayeb H.H. Sainsbury F. Nanoemulsions in drug delivery: Formulation to medical application. Nanomedicine 2018 13 19 2507 2525 10.2217/nnm‑2018‑0088 30265218
    [Google Scholar]
  51. Jaiswal M Dudhe R Sharma PK Nanoemulsion: An advanced mode of drug delivery system. 2015
  52. Patel R.B. Patel M.R. Thakore S.D. Patel B.G. Nanoemulsion as a valuable nanostructure platform for pharmaceutical drug delivery. In: Nano-and Microscale Drug Delivery Systems. Amsterdam, Netherlands Elsevier 2017 321 341 10.1016/B978‑0‑323‑52727‑9.00017‑0
    [Google Scholar]
  53. Sutradhar K.B. Amin M.L. Nanoemulsions: Increasing possibilities in drug delivery. Eur. J. Nanomed. 2013 5 2 97 110 10.1515/ejnm‑2013‑0001
    [Google Scholar]
  54. Kumar M. Bishnoi R.S. Shukla A.K. Jain C.P. Techniques for formulation of nanoemulsion drug delivery system: A review. Prev. Nutr. Food Sci. 2019 24 3 225 234 10.3746/pnf.2019.24.3.225 31608247
    [Google Scholar]
  55. Halnor V.V. Pande V.V. Borawake D.D. Nagare H.S. Nanoemulsion: A novel platform for drug delivery system. J Mater Sci Nanotechnol 2018 6 1 104
    [Google Scholar]
  56. Singh Y. Meher J.G. Raval K. Nanoemulsion: Concepts, development and applications in drug delivery. J. Control. Release 2017 252 28 49 10.1016/j.jconrel.2017.03.008 28279798
    [Google Scholar]
  57. Yukuyama M.N. Ghisleni D.D.M. Nanoemulsion: Process selection and application in cosmetics–a review. Int. J. Cosmet. Sci. 2016 38 1 13 24 10.1111/ics.12260 26171789
    [Google Scholar]
  58. Algahtani M.S. Ahmad M.Z. Ahmad J. Investigation of factors influencing formation of nanoemulsion by spontaneous emulsification: Impact on droplet size, polydispersity index, and stability. Bioengineering 2022 9 8 384 10.3390/bioengineering9080384 36004909
    [Google Scholar]
  59. Haro-González J.N. Castillo-Herrera G.A. Martínez-Velázquez M. Espinosa-Andrews H. Clove essential oil (Syzygium aromaticum L. Myrtaceae): Extraction, chemical composition, food applications, and essential bioactivity for human health. Molecules 2021 26 21 6387 10.3390/molecules26216387 34770801
    [Google Scholar]
  60. Kaur K. Kaushal S. Rani R. Chemical composition, antioxidant and antifungal potential of clove (Syzygium aromaticum) essential oil, its major compound and its derivatives. J. Essent. Oil-Bear. Plants 2019 22 5 1195 1217 10.1080/0972060X.2019.1688689
    [Google Scholar]
  61. Tiwari P. Verma R. Ahirwar D. Chandy A. Dwivedi S. Evaluation of anxiolytic effect of Syzygium aromaticum: A traditional herb of India. Asian Pac. J. Trop. Dis. 2014 4 4 S77 S80 10.1016/S2222‑1808(14)60418‑7
    [Google Scholar]
  62. Arora P. Antimicrobial activity of secondary metabolites in medicinal plants: An update. BIO Web Conf 2024 86 3 10.1051/bioconf/20248601040.
    [Google Scholar]
  63. Nagaraju P.G. Sengupta P. Chicgovinda P.P. Rao P.J. Nanoencapsulation of clove oil and study of physicochemical properties, cytotoxic, hemolytic, and antioxidant activities. J. Food Process Eng. 2021 44 4 13645 10.1111/jfpe.13645
    [Google Scholar]
  64. da Silva Campelo M. Câmara Neto J.F. de Souza Á.L. Clove volatile oil-loaded nanoemulsion reduces the anxious-like behavior in adult zebrafish. Daru 2023 31 2 183 192 10.1007/s40199‑023‑00473‑z 37639147
    [Google Scholar]
  65. Al Khouri Fallouh N. Roblot-Treupel L. Fessi H. Devissaguet J.P. Puisieux F. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int. J. Pharm. 1986 28 2-3 125 132 10.1016/0378‑5173(86)90236‑X
    [Google Scholar]
  66. Guterres S.S. Poletto F.S. Colomé L.M. Raffin R.P. Pohlmann A.R. Polymeric nanocapsules for drug delivery: An overview. In: Colloids in Drug Delivery. 1st Ed Taylor Francis/CRC Press 2010 71 97 10.1201/9781439818268‑c3
    [Google Scholar]
  67. Reimondez-Troitiño S. Alcalde I. Csaba N. Polymeric nanocapsules: A potential new therapy for corneal wound healing. Drug Deliv. Transl. Res. 2016 6 6 708 721 10.1007/s13346‑016‑0312‑0 27392604
    [Google Scholar]
  68. El-Say K.M. El-Sawy H.S. Polymeric nanoparticles: Promising platform for drug delivery. Int. J. Pharm. 2017 528 1-2 675 691 10.1016/j.ijpharm.2017.06.052 28629982
    [Google Scholar]
  69. Guterres S.S. Alves M.P. Pohlmann A.R. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2007 2 10.1177/117739280700200002 21901071
    [Google Scholar]
  70. Kothamasu P. Kanumur H. Ravur N. Maddu C. Parasuramrajam R. Thangavel S. Nanocapsules: The weapons for novel drug delivery systems. Bioimpacts 2012 2 2 71 81 23678444
    [Google Scholar]
  71. Kumar S. Chauhan N. Gopal M. Kumar R. Dilbaghi N. Development and evaluation of alginate–chitosan nanocapsules for controlled release of acetamiprid. Int. J. Biol. Macromol. 2015 81 631 637 10.1016/j.ijbiomac.2015.08.062 26321424
    [Google Scholar]
  72. Yousefi Rizi H.A. Shin D.H. Yousefi Rizi S. Polymeric nanoparticles in cancer chemotherapy: A narrative review. Iran. J. Public Health 2022 51 2 226 239 10.18502/ijph.v51i2.8677 35866132
    [Google Scholar]
  73. Deng S. Gigliobianco M.R. Censi R. Di Martino P. Polymeric nanocapsules as nanotechnological alternative for drug delivery system: Current status, challenges and opportunities. Nanomaterials 2020 10 5 847 10.3390/nano10050847 32354008
    [Google Scholar]
  74. Lima A.L. Gratieri T. Cunha-Filho M. Gelfuso G.M. Polymeric nanocapsules: A review on design and production methods for pharmaceutical purpose. Methods 2022 199 54 66 10.1016/j.ymeth.2021.07.009 34333117
    [Google Scholar]
  75. Karami Z. Saghatchi Zanjani M.R. Hamidi M. Nanoemulsions in CNS drug delivery: Recent developments, impacts and challenges. Drug Discov. Today 2019 24 5 1104 1115 10.1016/j.drudis.2019.03.021 30914298
    [Google Scholar]
  76. Lesjak M. Beara I. Simin N. Antioxidant and anti-inflammatory activities of quercetin and its derivatives. J. Funct. Foods 2018 40 68 75 10.1016/j.jff.2017.10.047
    [Google Scholar]
  77. Andrijauskaite K. Morris J. Wargovich M.J. Natural anticancer agents: Modifying the epigenome to prevent and treat cancer. In: Epigenetics of cancer prevention. Amsterdam, Netherlands Elsevier 2019 49 73 10.1016/B978‑0‑12‑812494‑9.00003‑2
    [Google Scholar]
  78. Larson A.J. Symons J.D. Jalili T. Quercetin: A treatment for hypertension?—A review of efficacy and mechanisms. Pharmaceuticals 2010 3 1 237 250 10.3390/ph3010237 27713250
    [Google Scholar]
  79. Sun Y. Li C. Li Z. Quercetin as an antiviral agent inhibits the Pseudorabies virus in vitro and in vivo. Virus Res. 2021 305 198556 10.1016/j.virusres.2021.198556 34492238
    [Google Scholar]
  80. Zhu S Wang H Zhang J Yu C Liu C. Antiasthmatic activity of quercetin glycosides in neonatal asthmatic rats. 3 Biotech 2019 9 5 189 10.1007/s13205‑019‑1618‑7
    [Google Scholar]
  81. Nguyen T.L.A. Bhattacharya D. Antimicrobial activity of quercetin: An approach to its mechanistic principle. Molecules 2022 27 8 2494 10.3390/molecules27082494 35458691
    [Google Scholar]
  82. Samad N. Saleem A. Yasmin F. Shehzad M.A. Quercetin protects against stress-induced anxiety- and depression-like behavior and improves memory in male mice. Physiol. Res. 2018 67 5 795 808 10.33549/physiolres.933776 30044120
    [Google Scholar]
  83. Kandemir K. Tomas M. McClements D.J. Capanoglu E. Recent advances on the improvement of quercetin bioavailability. Trends Food Sci. Technol. 2022 119 192 200 10.1016/j.tifs.2021.11.032
    [Google Scholar]
  84. Mahmoud K.Y. Elhesaisy N.A. Rashed A.R. Exploring the potential of intranasally administered naturally occurring quercetin loaded into polymeric nanocapsules as a novel platform for the treatment of anxiety. Sci. Rep. 2023 13 1 510 10.1038/s41598‑023‑27665‑6 36627363
    [Google Scholar]
  85. Erdő F. Bors L.A. Farkas D. Bajza Á. Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 2018 143 155 170 10.1016/j.brainresbull.2018.10.009 30449731
    [Google Scholar]
  86. Samimi S. Maghsoudnia N. Eftekhari R.B. Dorkoosh F. Lipid-based nanoparticles for drug delivery systems. In: Micro and Nano Technologies. Amsterdam, Netherlands Elsevier 2019 47 76 10.1016/B978‑0‑12‑814031‑4.00003‑9
    [Google Scholar]
  87. Bangham A.D. Surrogate cells or trojan horses. The discovery of liposomes. BioEssays 1995 17 12 1081 1088 10.1002/bies.950171213 8634070
    [Google Scholar]
  88. Pande S. Liposomes for drug delivery: Review of vesicular composition, factors affecting drug release and drug loading in liposomes. Artif. Cells Nanomed. Biotechnol. 2023 51 1 428 440 10.1080/21691401.2023.2247036 37594208
    [Google Scholar]
  89. Kumari S. Goyal A. Sönmez Gürer E. Bioactive loaded novel nano-formulations for targeted drug delivery and their therapeutic potential. Pharmaceutics 2022 14 5 1091 10.3390/pharmaceutics14051091 35631677
    [Google Scholar]
  90. Fan Y. Zhang Q. Development of liposomal formulations: From concept to clinical investigations. Asian J Pharm Sci 2013 8 2 81 87 10.1016/j.ajps.2013.07.010
    [Google Scholar]
  91. Nsairat H. Khater D. Sayed U. Odeh F. Al Bawab A. Alshaer W. Liposomes: Structure, composition, types, and clinical applications. Heliyon 2022 8 5 09394 10.1016/j.heliyon.2022.e09394 35600452
    [Google Scholar]
  92. Kotla N.G. Chandrasekar B. Rooney P. Biomimetic lipid-based nanosystems for enhanced dermal delivery of drugs and bioactive agents. ACS Biomater. Sci. Eng. 2017 3 7 1262 1272 10.1021/acsbiomaterials.6b00681 33440514
    [Google Scholar]
  93. Song X. Wang Y. Gao L. Mechanism of antioxidant properties of quercetin and quercetin-DNA complex. J. Mol. Model. 2020 26 6 133 10.1007/s00894‑020‑04356‑x 32399900
    [Google Scholar]
  94. Islam M.S. Hossain R. Ahmed T. Anxiolytic-like effect of quercetin possibly through GABA receptor interaction pathway: In vivo and in silico studies. Molecules 2022 27 21 7149 10.3390/molecules27217149 36363979
    [Google Scholar]
  95. Ugwu P.I. Ben-Azu B. Ugwu S.U. Preventive putative mechanisms involved in the psychopathologies of mice passively coping with psychosocial defeat stress by quercetin. Brain Res. Bull. 2022 183 127 141 10.1016/j.brainresbull.2022.03.004 35278662
    [Google Scholar]
  96. Li Y. Yao J. Han C. Quercetin, inflammation and immunity. Nutrients 2016 8 3 167 10.3390/nu8030167 26999194
    [Google Scholar]
  97. Priprem A. Watanatorn J. Sutthiparinyanont S. Phachonpai W. Muchimapura S. Anxiety and cognitive effects of quercetin liposomes in rats. Nanomedicine 2008 4 1 70 78 10.1016/j.nano.2007.12.001 18249157
    [Google Scholar]
  98. Siyal F.J. Siddiqui R.A. Memon Z. Eugenol and its liposome-based nano carrier reduce anxiety by inhibiting glyoxylase-1 expression in mice. Braz. J. Biol. 2023 83 251219 10.1590/1519‑6984.251219 34669914
    [Google Scholar]
  99. Handjani R.M. Ribier A. Vanlerberghe G. Zabotto A. Griat J. Cosmetic and pharmaceutical compositions containing niosomes and a water-soluble polyamide, and a process for preparing these compositions. US Patent 4830857A 1989
    [Google Scholar]
  100. Sahin N.O. Niosomes as nanocarrier systems. Nanomater Nanosyst Biomed Appl 2007 67 81
    [Google Scholar]
  101. Ruckmani K. Sankar V. Formulation and optimization of Zidovudine niosomes. AAPS PharmSciTech 2010 11 3 1119 1127 10.1208/s12249‑010‑9480‑2 20635228
    [Google Scholar]
  102. Bhardwaj P. Tripathi P. Gupta R. Pandey S. Niosomes: A review on niosomal research in the last decade. J. Drug Deliv. Sci. Technol. 2020 56 101581 10.1016/j.jddst.2020.101581
    [Google Scholar]
  103. Bartelds R. Nematollahi M.H. Pols T. Niosomes, an alternative for liposomal delivery. PLoS One 2018 13 4 0194179 10.1371/journal.pone.0194179 29649223
    [Google Scholar]
  104. Khoee S. Yaghoobian M. Niosomes: A novel approach in modern drug delivery systems. In: Nanostructures for drug delivery. Amsterdam, Netherlands Elsevier 2017 207 237 10.1016/B978‑0‑323‑46143‑6.00006‑3
    [Google Scholar]
  105. Cerqueira-Coutinho C. Dos Santos E.P. Mansur C.R.E. Niosomes as nano-delivery systems in the pharmaceutical field. Crit. Rev. Ther. Drug Carrier Syst. 2016 33 2 195 212 10.1615/CritRevTherDrugCarrierSyst.2016016167
    [Google Scholar]
  106. Chandu V.P. Arunachalam A. Jeganath S. Yamini K. Tharangini K. Chaitanya G. Niosomes: A novel drug delivery system. Int. J. Novel Trends Pharm. Sci. 2012 2 1 25 31
    [Google Scholar]
  107. Marianecci C. Di Marzio L. Rinaldi F. Niosomes from 80s to present: The state of the art. Adv. Colloid Interface Sci. 2014 205 187 206 10.1016/j.cis.2013.11.018 24369107
    [Google Scholar]
  108. Gharbavi M. Amani J. Kheiri-Manjili H. Danafar H. Sharafi A. Niosome: A promising nanocarrier for natural drug delivery through blood‐brain barrier. Adv. Pharmacol. Sci. 2018 2018 1 1 15 10.1155/2018/6847971 30651728
    [Google Scholar]
  109. Rickels K. Khalid-Khan S. Rynn M. Buspirone in the treatment of anxiety disorders. Anxiety Disorders 2003 381 397
    [Google Scholar]
  110. Mathure D. Madan J.R. Gujar K.N. Tupsamundre A. Ranpise H.A. Dua K. Formulation and evaluation of niosomal in situ nasal gel of a serotonin receptor agonist, buspirone hydrochloride for the brain delivery via intranasal route. Pharm. Nanotechnol. 2018 6 1 69 78 10.2174/2211738506666180130105919 29380709
    [Google Scholar]
  111. Pandey S. Shaikh F. Gupta A. Tripathi P. Yadav J.S. A recent update: Solid lipid nanoparticles for effective drug delivery. Adv. Pharm. Bull. 2022 12 1 17 33 35517874
    [Google Scholar]
  112. Sailaja A.K. Amareshwar P. Chakravarty P. Formulation of solid lipid nanoparticles and their applications. J Curr Pharma Res 2011 1 2 197 10.33786/JCPR.2011.v01i02.019
    [Google Scholar]
  113. Dudhipala N. Veerabrahma K. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug Dev. Ind. Pharm. 2015 41 12 1968 1977 10.3109/03639045.2015.1024685 25830370
    [Google Scholar]
  114. Geszke-Moritz M. Moritz M. Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies. Mater. Sci. Eng. C 2016 68 982 994 10.1016/j.msec.2016.05.119 27524099
    [Google Scholar]
  115. Mukherjee S. Ray S. Thakur R.S. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J. Pharm. Sci. 2009 71 4 349 358 10.4103/0250‑474X.57282 20502539
    [Google Scholar]
  116. Gordillo-Galeano A. Mora-Huertas C.E. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Eur. J. Pharm. Biopharm. 2018 133 285 308 10.1016/j.ejpb.2018.10.017 30463794
    [Google Scholar]
  117. Üner M. Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomedicine 2007 2 3 289 300 18019829
    [Google Scholar]
  118. Das S. Ng W.K. Tan R.B.H. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur. J. Pharm. Sci. 2012 47 1 139 151 10.1016/j.ejps.2012.05.010 22664358
    [Google Scholar]
  119. Galpern W.R. Miller L.G. Greenblatt D.J. Shader R.I. Differential effects of chronic lorazepam and alprazolam on benzodiazepine binding and GABA A ‐receptor function. Br. J. Pharmacol. 1990 101 4 839 842 10.1111/j.1476‑5381.1990.tb14167.x 1964820
    [Google Scholar]
  120. Singh A.P. Saraf S.K. Saraf S.A. SLN approach for nose-to-brain delivery of alprazolam. Drug Deliv. Transl. Res. 2012 2 6 498 507 10.1007/s13346‑012‑0110‑2 25787328
    [Google Scholar]
  121. Tapeinos C. Battaglini M. Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control. Release 2017 264 306 332 10.1016/j.jconrel.2017.08.033 28844756
    [Google Scholar]
  122. Ganesan P. Narayanasamy D. Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain. Chem. Pharm. 2017 6 37 56 10.1016/j.scp.2017.07.002
    [Google Scholar]
  123. Selvaraj K. Gowthamarajan K. Karri V.V.S.R. Nose to brain transport pathways an overview: Potential of nanostructured lipid carriers in nose to brain targeting. Artif. Cells Nanomed. Biotechnol. 2018 46 8 2088 2095 29282995
    [Google Scholar]
  124. Müller R.H. Radtke M. Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002 242 1-2 121 128 10.1016/S0378‑5173(02)00180‑1 12176234
    [Google Scholar]
  125. Nsairat H. Khater D. Odeh F. Lipid nanostructures for targeting brain cancer. Heliyon 2021 7 9 07994 10.1016/j.heliyon.2021.e07994 34632135
    [Google Scholar]
  126. Nguyen V.H. Thuy V.N. Van T.V. Dao A.H. Lee B-J. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. OpenNano 2022 8 100064 10.1016/j.onano.2022.100064
    [Google Scholar]
  127. Weber S. Zimmer A. Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art. Eur. J. Pharm. Biopharm. 2014 86 1 7 22 10.1016/j.ejpb.2013.08.013 24007657
    [Google Scholar]
  128. Jaiswal P. Gidwani B. Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif. Cells Nanomed. Biotechnol. 2016 44 1 27 40 10.3109/21691401.2014.909822 24813223
    [Google Scholar]
  129. Elmowafy M. Al-Sanea M.M. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm. J. 2021 29 9 999 1012 10.1016/j.jsps.2021.07.015 34588846
    [Google Scholar]
  130. Khosa A. Reddi S. Saha R.N. Nanostructured lipid carriers for site-specific drug delivery. Biomed. Pharmacother. 2018 103 598 613 10.1016/j.biopha.2018.04.055 29677547
    [Google Scholar]
  131. Fu Y.S. Chen T.H. Weng L. Huang L. Lai D. Weng C.F. Pharmacological properties and underlying mechanisms of curcumin and prospects in medicinal potential. Biomed. Pharmacother. 2021 141 111888 10.1016/j.biopha.2021.111888 34237598
    [Google Scholar]
  132. Chen Y. Lu Y. Lee R.J. Xiang G. Nano encapsulated curcumin: And its potential for biomedical applications. Int. J. Nanomedicine 2020 15 3099 3120 10.2147/IJN.S210320 32431504
    [Google Scholar]
  133. Rubab S. Naeem K. Rana I. Enhanced neuroprotective and antidepressant activity of curcumin-loaded nanostructured lipid carriers in lipopolysaccharide-induced depression and anxiety rat model. Int. J. Pharm. 2021 603 120670 10.1016/j.ijpharm.2021.120670 33964337
    [Google Scholar]
  134. Arif S.T. Khan M.A. Zaman S. Enhanced antidepressant activity of nanostructured lipid carriers containing levosulpiride in behavioral despair tests in mice. Pharmaceuticals 2023 16 9 1220 10.3390/ph16091220 37765028
    [Google Scholar]
  135. Akrab S.N.A. Al Gawhary N.E. Shafik A.N. Morcos G.N.B. Wissa M.Y. The role of mosapride and levosulpiride in gut function and glycemic control in diabetic rats. Arab J. Gastroenterol. 2023 24 2 109 116 10.1016/j.ajg.2023.01.008 36878815
    [Google Scholar]
  136. Joe J. Levosulpiride-induced neurological adverse effects: A prospective study from a tertiary care center. Ann. Indian Acad. Neurol. 2020 23 2 174 176 10.4103/aian.AIAN_449_18 32189857
    [Google Scholar]
  137. Manda R.A. Bamel V. Singhal A. Gupta N. To assess the impact of orally given itopride and levosulpride on non-ulcer dyspepsia. Int. J. Med. Public Health 2024 14 3 1 5
    [Google Scholar]
  138. Arif S.T. Zaman S. Khan M.A. Augmented oral bioavailability and prokinetic activity of levosulpiride delivered in nanostructured lipid carriers. Pharmaceutics 2022 14 11 2347 10.3390/pharmaceutics14112347 36365165
    [Google Scholar]
  139. Yasir M. Chauhan I. Zafar A. Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: Formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation. J. Drug Deliv. Sci. Technol. 2021 61 102164 10.1016/j.jddst.2020.102164
    [Google Scholar]
  140. Noorulla K.M. Yasir M. Muzaffar F. Intranasal delivery of chitosan decorated nanostructured lipid carriers of Buspirone for brain targeting: Formulation development, optimization and In-Vivo preclinical evaluation. J. Drug Deliv. Sci. Technol. 2022 67 102939 10.1016/j.jddst.2021.102939
    [Google Scholar]
  141. Trimble M.R. Carbamazepine and mood: Evidence from patients with seizure disorders. J. Clin. Psychiatry 1988 49 Suppl. 7 12 3280564
    [Google Scholar]
  142. Bridwell R.E. Brown S. Clerkin S. Birdsong S. Long B. Neurologic toxicity of carbamazepine in treatment of trigeminal neuralgia. Am. J. Emerg. Med. 2022 55 231.e3 231.e5 10.1016/j.ajem.2022.01.044 35101289
    [Google Scholar]
  143. Khan N. Shah F.A. Rana I. Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity. Int. J. Pharm. 2020 577 119033 10.1016/j.ijpharm.2020.119033 31954864
    [Google Scholar]
  144. Aranaz I. Alcántara A.R. Civera M.C. Chitosan: An overview of its properties and applications. Polymers 2021 13 19 3256 10.3390/polym13193256 34641071
    [Google Scholar]
  145. Giri T.K. Chitosan based nanoparticulate system for controlled delivery of biological macromolecules. In: Nanomater drug Deliv 2019 435 5 10.1016/B978‑0‑12‑816505‑8.00004‑7
    [Google Scholar]
  146. Tiyaboonchai W. Chitosan nanoparticles: A promising system for drug delivery. Naresuan Univ J Sci Technol 2003 11 3 51 66
    [Google Scholar]
  147. Bashir S.M. Ahmed Rather G. Patrício A. Chitosan nanoparticles: A versatile platform for biomedical applications. Materials 2022 15 19 6521 10.3390/ma15196521 36233864
    [Google Scholar]
  148. Grenha A. Chitosan nanoparticles: A survey of preparation methods. J. Drug Target. 2012 20 4 291 300 10.3109/1061186X.2011.654121 22296336
    [Google Scholar]
  149. Wu H. Zhou Y. Wang Y. Current state and future directions of intranasal delivery route for central nervous system disorders: A scientometric and visualization analysis. Front. Pharmacol. 2021 12 717192 10.3389/fphar.2021.717192 34322030
    [Google Scholar]
  150. Bari N.K. Fazil M. Hassan M.Q. Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder. Int. J. Biol. Macromol. 2015 81 49 59 10.1016/j.ijbiomac.2015.07.041 26210037
    [Google Scholar]
  151. Zarate C.A. Manji H.K. Riluzole in psychiatry: A systematic review of the literature. Expert Opin. Drug Metab. Toxicol. 2008 4 9 1223 1234 10.1517/17425255.4.9.1223 18721116
    [Google Scholar]
  152. Volkova T. Simonova O. Perlovich G. Controlling the solubility, release rate and permeation of riluzole with cyclodextrins. Pharmaceutics 2024 16 6 757 10.3390/pharmaceutics16060757 38931879
    [Google Scholar]
  153. Nabi B. Rehman S. Fazil M. Khan S. Baboota S. Ali J. Riluzole-loaded nanoparticles to alleviate the symptoms of neurological disorders by attenuating oxidative stress. Drug Dev. Ind. Pharm. 2020 46 3 471 483 10.1080/03639045.2020.1730396 32057274
    [Google Scholar]
  154. Stein D.J. Ahokas A. Márquez M.S. Agomelatine in generalized anxiety disorder: An active comparator and placebo-controlled study. J. Clin. Psychiatry 2014 75 4 362 368 10.4088/JCP.13m08433 24569045
    [Google Scholar]
  155. Stein D.J. Ahokas A. Jarema M. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. Eur. Neuropsychopharmacol. 2017 27 5 526 537 10.1016/j.euroneuro.2017.02.007 28298261
    [Google Scholar]
  156. Weston N.M. Gibbs D. Bird C.I.V. Historic psychedelic drug trials and the treatment of anxiety disorders. Depress. Anxiety 2020 37 12 1261 1279 10.1002/da.23065 32627308
    [Google Scholar]
  157. Fuentes J.J. Fonseca F. Elices M. Farré M. Torrens M. Therapeutic use of LSD in psychiatry: A systematic review of randomized-controlled clinical trials. Front. Psychiatry 2020 10 943 10.3389/fpsyt.2019.00943 32038315
    [Google Scholar]
  158. Krystal J.H. Mathew S.J. DʼSouza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010 24 8 669 693 10.2165/11533230‑000000000‑00000 20658799
    [Google Scholar]
  159. Bergink V. Westenberg H.G.M. Metabotropic glutamate II receptor agonists in panic disorder: A double blind clinical trial with LY354740. Int. Clin. Psychopharmacol. 2005 20 6 291 293 10.1097/00004850‑200511000‑00001 16192835
    [Google Scholar]
  160. Dunayevich E. Erickson J. Levine L. Landbloom R. Schoepp D.D. Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008 33 7 1603 1610 10.1038/sj.npp.1301531 17712352
    [Google Scholar]
  161. Kent J.M. Daly E. Kezic I. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016 67 66 73 10.1016/j.pnpbp.2016.01.009 26804646
    [Google Scholar]
  162. Barros-Santos T. Silva K.S.O. Libarino-Santos M. Effects of chronic treatment with new strains of Lactobacillus plantarum on cognitive, anxiety- and depressive-like behaviors in male mice. PLoS One 2020 15 6 0234037 10.1371/journal.pone.0234037 32559185
    [Google Scholar]
  163. Smith K.S. Greene M.W. Babu J.R. Frugé A.D. Psychobiotics as treatment for anxiety, depression, and related symptoms: A systematic review. Nutr. Neurosci. 2021 24 12 963 977 10.1080/1028415X.2019.1701220 31858898
    [Google Scholar]
  164. Daraee H. Etemadi A. Kouhi M. Alimirzalu S. Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif. Cells Nanomed. Biotechnol. 2016 44 1 381 391 10.3109/21691401.2014.953633 25222036
    [Google Scholar]
  165. Alavi M. Karimi N. Safaei M. Application of various types of liposomes in drug delivery systems. Adv. Pharm. Bull. 2017 7 1 3 9 10.15171/apb.2017.002 28507932
    [Google Scholar]
  166. Parambath A. Engineering of biomaterials for drug delivery systems: Beyond polyethylene glycol. United Kingdom Woodhead Publishing 2018
    [Google Scholar]
  167. Bozzuto G. Molinari A. Liposomes as nanomedical devices. Int. J. Nanomedicine 2015 10 975 999 10.2147/IJN.S68861 25678787
    [Google Scholar]
  168. Gabizon A.A. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001 19 4 424 436 10.1081/CNV‑100103136 11405181
    [Google Scholar]
  169. van den Hoven J.M. Nemes R. Metselaar J.M. Complement activation by PEGylated liposomes containing prednisolone. Eur. J. Pharm. Sci. 2013 49 2 265 271 10.1016/j.ejps.2013.03.007 23528740
    [Google Scholar]
  170. Tarhini M. Greige-Gerges H. Elaissari A. Protein-based nanoparticles: From preparation to encapsulation of active molecules. Int. J. Pharm. 2017 522 1-2 172 197 10.1016/j.ijpharm.2017.01.067 28188876
    [Google Scholar]
  171. Mariam J. Sivakami S. Dongre P.M. Albumin corona on nanoparticles – a strategic approach in drug delivery. Drug Deliv. 2016 23 8 2668 2676 10.3109/10717544.2015.1048488 26056719
    [Google Scholar]
  172. Zeeshan F. Madheswaran T. Panneerselvam J. Taliyan R. Kesharwani P. Human serum albumin as multifunctional nanocarrier for cancer therapy. J. Pharm. Sci. 2021 110 9 3111 3117 10.1016/j.xphs.2021.05.001 33989679
    [Google Scholar]
  173. Wartlick H. Spänkuch-Schmitt B. Strebhardt K. Kreuter J. Langer K. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J. Control. Release 2004 96 3 483 495 10.1016/j.jconrel.2004.01.029 15120904
    [Google Scholar]
  174. Anagnostou K. Stylianakis M. Michaleas S. Skouras A. Biodegradable nanomaterials. In: Nanomaterials for Clinical Applications. Amsterdam, Netherlands Elsevier 2020 123 157 10.1016/B978‑0‑12‑816705‑2.00005‑9
    [Google Scholar]
  175. Singh N. Joshi A. Toor A.P. Verma G. Drug delivery: Advancements and challenges. In: Nanostructures for drug delivery. Amsterdam, Netherlands Elsevier 2017 865 886 10.1016/B978‑0‑323‑46143‑6.00027‑0
    [Google Scholar]
  176. Prabha A.S. Dorothy R. Jancirani S. Rajendran S. Singh G. Kumaran S.S. Recent advances in the study of toxicity of polymer-based nanomaterials. Nanotoxicity 2020 143 165
    [Google Scholar]
  177. Grabowski N. Hillaireau H. Vergnaud J. Surface coating mediates the toxicity of polymeric nanoparticles towards human-like macrophages. Int. J. Pharm. 2015 482 1-2 75 83 10.1016/j.ijpharm.2014.11.042 25448553
    [Google Scholar]
  178. Krishnaswamy K. Orsat V. Sustainable delivery systems through green nanotechnology. In: Nano-and microscale drug delivery systems. Amsterdam, Netherlands Elsevier 2017 17 32 10.1016/B978‑0‑323‑52727‑9.00002‑9
    [Google Scholar]
  179. Palanikumar L. Al-Hosani S. Kalmouni M. pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics. Commun. Biol. 2020 3 1 95 10.1038/s42003‑020‑0817‑4 32127636
    [Google Scholar]
  180. Yang P. Gai S. Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem. Soc. Rev. 2012 41 9 3679 3698 10.1039/c2cs15308d 22441299
    [Google Scholar]
  181. Li Z. Barnes J.C. Bosoy A. Stoddart J.F. Zink J.I. Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev. 2012 41 7 2590 2605 10.1039/c1cs15246g 22216418
    [Google Scholar]
  182. Lu J. Liong M. Li Z. Zink J.I. Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 2010 6 16 1794 1805 10.1002/smll.201000538
    [Google Scholar]
  183. Bancos S. Stevens D.L. Tyner K.M. Effect of silica and gold nanoparticles on macrophage proliferation, activation markers, cytokine production, and phagocytosis in vitro. Int. J. Nanomedicine 2014 10 183 206 25565813
    [Google Scholar]
  184. Yang L. Yan Q. Zhao J. The role of potassium channel in silica nanoparticle-induced inflammatory effect in human vascular endothelial cells in vitro. Toxicol. Lett. 2013 223 1 16 24 10.1016/j.toxlet.2013.08.017 24001805
    [Google Scholar]
/content/journals/cprr/10.2174/0126660822381093251114064131
Loading
Amelioration of Anxiety Disorders Using Nanotechnology-Based Drug Delivery Systems
Bentham Science Publishers ; https://doi.org/10.2174/0126660822381093251114064131
/content/journals/cprr/10.2174/0126660822381093251114064131
/content/journals/cprr/10.2174/0126660822381093251114064131
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Anxiety disorders ; nanoformulations ; anxiolytic ; nanocarriers ; novel drug delivery ; anxiety disorder

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test